GLP-1 Before Surgery: Anesthesia, Colonoscopy, and Sedation

Glucagon-like peptide-1 receptor agonists have transformed the clinical management of obesity and type 2 diabetes. Medications such as Ozempic, Wegovy, and Mounjaro now reach a substantial proportion of surgical candidates. Consequently, perioperative teams face a distinct challenge tied to how these agents alter gastrointestinal physiology. Understanding this mechanism is essential for anesthesiologists, gastroenterologists, and surgeons who manage patients before sedation.

The relevance of this issue extends across nearly every procedural setting. Colonoscopy, elective surgery, and outpatient sedation all depend on an accurate assumption about gastric contents. GLP-1 therapy disrupts that assumption in ways that standard preparation instructions do not fully address. As a result, procedural teams increasingly require dedicated protocols for patients using these medications.

The Pharmacological Basis of Delayed Gastric Emptying

GLP-1 receptor agonists act on multiple physiological pathways to produce sustained weight loss and improved glycemic control. Beyond stimulating insulin secretion, these agents slow gastric motility through a mechanism often described as the ileal brake. This effect delays the transit of solid and liquid contents from the stomach into the small intestine. As a result, patients experience prolonged satiety, which supports the therapeutic goals of weight management.

This delayed emptying is not incidental to the therapeutic effect. It represents a core mechanism through which GLP-1 receptor agonists suppress appetite and reduce caloric intake. Clinicians have studied this pathway for decades in relation to satiety signaling. Consequently, the same mechanism that supports weight loss also alters how the stomach behaves before a procedure.

The same mechanism that supports appetite suppression creates a distinct procedural risk. Food and liquid may remain in the stomach far longer than standard fasting guidelines anticipate. Consequently, a patient who fasts appropriately by conventional standards may still present with retained gastric contents. This discrepancy forms the clinical basis for updated perioperative guidance.

Aspiration Risk During Sedation and Anesthesia

Aspiration occurs when gastric contents enter the airway and lungs during a period of reduced protective reflexes. Under normal circumstances, coughing and swallowing reflexes prevent this occurrence. Sedation and general anesthesia suppress these protective mechanisms, which increases vulnerability among patients with delayed gastric emptying. Individuals taking GLP-1 receptor agonists therefore carry an elevated baseline risk during any procedure requiring anesthesia.

The clinical consequences of aspiration extend well beyond the immediate procedure. Aspiration pneumonitis can develop rapidly following the chemical injury caused by gastric acid in the lungs. In more severe presentations, patients may progress toward acute respiratory failure requiring intensive care. Given these risks, procedural teams must treat GLP-1 use as a relevant factor during preoperative assessment.

Standard fasting protocols were developed without accounting for pharmacologically delayed gastric emptying. Guidelines commonly recommend withholding solid food for six to eight hours before a procedure. This window assumes a normal rate of gastric transit. That assumption often does not hold for patients on GLP-1 therapy, particularly during dose titration.

Consequently, adherence to standard fasting instructions does not guarantee an empty stomach in this population. A patient may follow every preoperative instruction precisely and still arrive with retained contents. This gap between instruction and physiological reality is central to current guidance revisions. Procedural teams are therefore encouraged to look beyond fasting duration alone.

Current Multisociety Guidance

Recognizing inconsistencies across earlier recommendations, several major medical organizations issued unified guidance in 2024. The American Society of Anesthesiologists collaborated with the American Gastroenterological Association and additional specialty societies. This multisociety consensus emphasized individualized risk assessment over rigid, one-size-fits-all discontinuation rules. Most patients, according to this guidance, may continue GLP-1 therapy through the day of an elective procedure.

The guidance favors shared decision-making among the patient, the prescribing clinician, and the procedural team. This approach balances the metabolic benefits of continued therapy against the procedural risks of delayed gastric emptying. Clinicians are encouraged to evaluate symptom burden rather than rely solely on dosing schedule. Notably, patients without gastrointestinal symptoms face a materially different risk profile than those experiencing nausea or early satiety.

Several clinical variables inform this individualized assessment. Symptom severity during the medication titration phase carries particular weight in decision-making. Higher doses are associated with an increased prevalence of gastrointestinal side effects. Additionally, comorbid conditions such as gastroparesis, bowel dysmotility, or Parkinson disease can compound delayed gastric emptying and warrant closer scrutiny.

This shift toward individualized assessment reflects an evolving evidence base. Earlier guidance relied heavily on dosing frequency as a proxy for risk. Emerging data instead point toward symptom presence as a stronger predictor of retained gastric contents. Consequently, procedural teams now place greater emphasis on a structured symptom history at the preoperative visit.

Distinguishing Daily and Weekly Formulations

Formulation and dosing frequency remain relevant when procedural teams determine whether to hold a medication. Daily oral formulations, including daily oral semaglutide, generally reach a shorter half-life than injectable counterparts. In cases where discontinuation is deemed appropriate, daily oral agents are typically held on the day of the procedure. This shorter interruption period reduces the duration of glycemic disruption in patients with type 2 diabetes.

Weekly injectable formulations, including weekly semaglutide and tirzepatide, require a longer discontinuation window when interruption is warranted. Earlier guidance from 2023 recommended withholding these agents for a full week before an elective procedure. Subsequent multisociety guidance has moved away from rigid discontinuation timelines. Instead, current recommendations favor individualized, symptom-based assessment over a fixed interval tied to dosing frequency.

Nevertheless, many procedural teams continue to reference the one-week interval as a conservative benchmark. This is particularly common in settings where structured symptom screening has not yet been implemented. Clinicians balancing multiple guidance documents may default to the more conservative approach. Over time, wider adoption of individualized protocols is expected to reduce this variability.

Colonoscopy-Specific Considerations

Colonoscopy preparation already requires a period of dietary restriction, which intersects directly with GLP-1 pharmacology. Standard bowel preparation regimens depend on adequate gastric and intestinal transit to clear the colon effectively. Delayed gastric emptying can interfere with the timing and completeness of this preparation. As a result, some patients on GLP-1 therapy experience inadequate bowel preparation despite following standard instructions.

Endoscopy societies have issued specific communication addressing this overlap. Patients reporting gastrointestinal symptoms before a scheduled colonoscopy warrant additional evaluation before proceeding. In select cases, a same-day point-of-care assessment can confirm whether the stomach is adequately empty. This step reduces the likelihood of procedure cancellation or aspiration during sedation.

Preoperative Strategies When Continuation is Preferred

When a care team elects to continue GLP-1 therapy through the procedure date, several mitigation strategies reduce aspiration risk. A twenty-four hour clear liquid diet before the procedure is among the most commonly applied interventions. This approach mirrors preparation protocols already used before colonoscopy and bariatric surgery. By limiting intake to liquids, the strategy reduces the volume of retained solid content in the stomach.

Point-of-care gastric ultrasound offers a direct method for confirming gastric emptying status before sedation begins. This bedside imaging technique allows clinicians to visually assess residual stomach contents. When ultrasound findings suggest a full stomach, the procedural team can modify the anesthesia plan accordingly. Rapid sequence induction, a technique designed to minimize unprotected airway exposure, represents one such modification.

Symptom screening on the day of the procedure remains a foundational safety step regardless of prior planning. Patients reporting nausea, vomiting, or an inability to tolerate oral intake require closer evaluation before sedation proceeds. These symptoms suggest active delayed gastric emptying beyond baseline pharmacological effects. In such cases, elective procedures may be postponed to reduce aspiration risk.

Clinical Implications for Procedural Planning

The growing prevalence of GLP-1 receptor agonist use carries direct implications for scheduling across obesity and type 2 diabetes populations. Anesthesiologists increasingly encounter these medications during routine preoperative assessment. Structured screening questions regarding GLP-1 use have therefore become a standard component of preoperative evaluation. This shift reflects a broader recognition that pharmacological changes to gastric physiology warrant deliberate clinical attention.

Effective management requires coordination among prescribing clinicians, procedural teams, and the patient. Prescribing clinicians can offer insight into dosing history, titration status, and symptom patterns relevant to risk stratification. Procedural teams, in turn, translate this information into concrete adjustments to fasting instructions or anesthesia technique. This collaborative model supports safer outcomes without unnecessarily discontinuing effective weight management or glycemic therapy.

Institutional protocols are also evolving to formalize this coordination. Some centers now embed GLP-1 screening directly into preoperative intake documentation. Others require confirmation of the most recent dose before scheduling sedation-dependent procedures. These operational changes reduce reliance on individual clinician judgment alone and support consistent, guideline-concordant care.

Conclusion

GLP-1 receptor agonists alter gastric motility through mechanisms that directly affect perioperative safety. Delayed gastric emptying increases the risk of aspiration during sedation and general anesthesia, even when standard fasting guidelines are followed. Multisociety guidance published in 2024 favors individualized, symptom-based risk assessment over rigid discontinuation rules tied to dosing frequency. Preoperative liquid diets and point-of-care gastric ultrasound offer practical tools for confirming gastric emptying when continuation of therapy is preferred. As the population of patients using these medications grows, procedural teams will likely refine screening protocols to reflect emerging evidence.

References

Hashash, J., Thompson, C. C., & Wang, A. Y. (2023). AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: Communication. Clinical Gastroenterology and Hepatology, 22(4), 705-707. https://doi.org/10.1016/j.cgh.2023.11.002

American Society of Anesthesiologists. (2024, October). New multi-society GLP-1 clinical practice guidance released [Press release]. https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance

Kindel, T. L., Wang, A. Y., Wadhwa, A., Schulman, A. R., Sharaiha, R. Z., Kroh, M., Ghanem, O. M., Levy, S., Joshi, G. P., & LaMasters, T. L. (2024). Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surgery for Obesity and Related Diseases, 20(12), 1183-1186. https://doi.org/10.1016/j.soard.2024.08.033